Identifying subsets of patients with retroperitoneal sarcoma who benefit from radiotherapy: an Interpretable AI reanalysis of the STRASS randomised trial.

Dimitris Bertsimas¹, Georgios Antonios Margonis², Angelos Koulouras¹, Martin Kreis³, Felix Balzer⁴, Murray F Brennan⁵, Sylvie Bonvalot⁶, Samuel Singer⁷

¹Operations Research Center, Massachusetts Institute of Technology, Cambridge, MA, USA.

²Operations Research Center, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of General and Visceral Surgery, Charité-Universitätsmedisin Berlin, Campus Benjamin Franklin, Berlin, Germany; Institute of Medical Informatics, Charité-Universitätsmedisin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

³Department of General and Visceral Surgery, Charité-Universitätsmedisin Berlin, Campus Benjamin Franklin, Berlin, Germany.

⁴Institute of Medical Informatics, Charité-Universitätsmedisin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

⁵Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

⁶Department of Surgical Oncology, Institut Curie, Université Paris Sciences et Lettres, Paris, France.

⁷Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: singers@mskcc.org.

PubMed DOI

Abstract

BACKGROUND: The European Organisation for Research and Treatment of Cancer's STRASS trial, the only completed randomised study of preoperative radiotherapy in retroperitoneal sarcoma, showed no overall benefit. Its subgroup analysis has been interpreted as supporting radiotherapy for all patients with liposarcoma, whereas the STREXIT extension has been interpreted as supporting radiotherapy for we…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.